Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psoriasis | 3 | 2022 | 51 | 1.580 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 166 | 1.460 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 404 | 1.100 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 94 | 0.990 |
Why?
|
| Dermatology | 2 | 2023 | 69 | 0.840 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2022 | 11 | 0.810 |
Why?
|
| Skin Diseases, Vesiculobullous | 2 | 2014 | 5 | 0.800 |
Why?
|
| Pemphigoid, Bullous | 1 | 2021 | 3 | 0.750 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 32 | 0.750 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 61 | 0.730 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 104 | 0.720 |
Why?
|
| Software | 1 | 2023 | 367 | 0.710 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 22 | 0.700 |
Why?
|
| Soaps | 1 | 2019 | 6 | 0.660 |
Why?
|
| Massage | 1 | 2019 | 9 | 0.660 |
Why?
|
| Tick-Borne Diseases | 1 | 2019 | 7 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 233 | 0.650 |
Why?
|
| Tick Bites | 1 | 2019 | 9 | 0.650 |
Why?
|
| Ticks | 1 | 2019 | 30 | 0.650 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 24 | 0.650 |
Why?
|
| Biological Products | 1 | 2020 | 94 | 0.640 |
Why?
|
| Mastectomy | 1 | 2019 | 52 | 0.640 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 125 | 0.630 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 45 | 0.630 |
Why?
|
| Facial Dermatoses | 2 | 2017 | 10 | 0.600 |
Why?
|
| Mycobacterium haemophilum | 1 | 2017 | 5 | 0.590 |
Why?
|
| Mycobacterium Infections | 1 | 2017 | 16 | 0.580 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 27 | 0.580 |
Why?
|
| Hyperpigmentation | 1 | 2017 | 5 | 0.580 |
Why?
|
| Lichen Planus | 1 | 2017 | 9 | 0.570 |
Why?
|
| Antifungal Agents | 3 | 2017 | 117 | 0.550 |
Why?
|
| Crohn Disease | 1 | 2017 | 113 | 0.520 |
Why?
|
| Tinea Versicolor | 2 | 2013 | 3 | 0.510 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 258 | 0.510 |
Why?
|
| Alternariosis | 1 | 2014 | 2 | 0.470 |
Why?
|
| Malassezia | 2 | 2017 | 6 | 0.470 |
Why?
|
| Humans | 25 | 2023 | 59343 | 0.440 |
Why?
|
| Acne Vulgaris | 2 | 2017 | 24 | 0.440 |
Why?
|
| Leprosy, Borderline | 1 | 2013 | 2 | 0.430 |
Why?
|
| Leprosy, Lepromatous | 1 | 2013 | 2 | 0.430 |
Why?
|
| Skin | 4 | 2017 | 351 | 0.410 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 1129 | 0.410 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 98 | 0.400 |
Why?
|
| Lymphangioma | 1 | 2011 | 3 | 0.390 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 26 | 0.390 |
Why?
|
| Biopsy | 5 | 2018 | 373 | 0.350 |
Why?
|
| Dermatitis, Perioral | 1 | 2009 | 1 | 0.340 |
Why?
|
| Drug Eruptions | 1 | 2009 | 13 | 0.340 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 93 | 0.320 |
Why?
|
| Dermatomycoses | 1 | 2009 | 13 | 0.320 |
Why?
|
| Influenza Vaccines | 1 | 2009 | 88 | 0.310 |
Why?
|
| Diagnosis, Differential | 4 | 2017 | 898 | 0.310 |
Why?
|
| Cephalexin | 1 | 2008 | 4 | 0.300 |
Why?
|
| Middle Aged | 9 | 2021 | 16242 | 0.280 |
Why?
|
| Nevus, Pigmented | 1 | 2006 | 20 | 0.270 |
Why?
|
| Male | 13 | 2020 | 27505 | 0.260 |
Why?
|
| Female | 9 | 2021 | 30847 | 0.230 |
Why?
|
| Adult | 6 | 2020 | 15745 | 0.230 |
Why?
|
| Folliculitis | 2 | 2017 | 6 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 722 | 0.220 |
Why?
|
| Retrospective Studies | 4 | 2021 | 5981 | 0.210 |
Why?
|
| Melanoma | 1 | 2006 | 334 | 0.210 |
Why?
|
| Adolescent | 5 | 2020 | 5921 | 0.210 |
Why?
|
| Granuloma Annulare | 1 | 2002 | 3 | 0.200 |
Why?
|
| Administration, Topical | 1 | 2021 | 52 | 0.190 |
Why?
|
| Endocrine System Diseases | 1 | 2001 | 10 | 0.190 |
Why?
|
| Child | 4 | 2020 | 4301 | 0.190 |
Why?
|
| Fluorouracil | 1 | 2021 | 54 | 0.190 |
Why?
|
| Seroconversion | 1 | 2020 | 4 | 0.180 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2020 | 6 | 0.180 |
Why?
|
| Keratosis | 1 | 2000 | 2 | 0.180 |
Why?
|
| Purpura | 1 | 2000 | 3 | 0.180 |
Why?
|
| Scurvy | 1 | 2000 | 2 | 0.180 |
Why?
|
| Conflict of Interest | 1 | 2020 | 35 | 0.180 |
Why?
|
| Skin Diseases | 1 | 2001 | 74 | 0.180 |
Why?
|
| Peer Review, Research | 1 | 2020 | 46 | 0.170 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 846 | 0.160 |
Why?
|
| Young Adult | 3 | 2020 | 4324 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2022 | 735 | 0.160 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2018 | 8 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2018 | 23 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 314 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 354 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 173 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2000 | 314 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2466 | 0.130 |
Why?
|
| Prevalence | 1 | 2020 | 1279 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2023 | 1908 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 293 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 189 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2325 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1128 | 0.120 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2014 | 33 | 0.110 |
Why?
|
| Granuloma | 1 | 2014 | 38 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5079 | 0.110 |
Why?
|
| Leprostatic Agents | 1 | 2013 | 3 | 0.110 |
Why?
|
| Clofazimine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Hypesthesia | 1 | 2013 | 8 | 0.110 |
Why?
|
| Mycobacterium leprae | 1 | 2013 | 6 | 0.110 |
Why?
|
| Dapsone | 1 | 2013 | 9 | 0.110 |
Why?
|
| Rifampin | 1 | 2013 | 23 | 0.110 |
Why?
|
| Contraindications | 1 | 2013 | 45 | 0.110 |
Why?
|
| Minocycline | 1 | 2013 | 25 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 43 | 0.100 |
Why?
|
| Blister | 1 | 2012 | 17 | 0.100 |
Why?
|
| Ultraviolet Therapy | 1 | 2012 | 13 | 0.100 |
Why?
|
| Aged | 2 | 2020 | 13308 | 0.100 |
Why?
|
| United States | 2 | 2020 | 7499 | 0.090 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 4 | 0.090 |
Why?
|
| Leg Dermatoses | 1 | 2009 | 3 | 0.090 |
Why?
|
| Prednisone | 1 | 2009 | 80 | 0.080 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2009 | 6 | 0.080 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2008 | 8 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 139 | 0.070 |
Why?
|
| Vaccination | 1 | 2009 | 337 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2009 | 193 | 0.070 |
Why?
|
| Nevus, Blue | 1 | 2006 | 2 | 0.070 |
Why?
|
| Epithelioid Cells | 1 | 2006 | 4 | 0.070 |
Why?
|
| MART-1 Antigen | 1 | 2006 | 8 | 0.070 |
Why?
|
| Shoulder | 1 | 2006 | 22 | 0.070 |
Why?
|
| S100 Proteins | 1 | 2006 | 21 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 344 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 40 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 134 | 0.060 |
Why?
|
| Melanocytes | 1 | 2006 | 78 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 276 | 0.060 |
Why?
|
| Infant | 1 | 2009 | 1527 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2018 | 5145 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1447 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2009 | 1838 | 0.060 |
Why?
|
| Animals | 1 | 2019 | 19620 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2020 | 22 | 0.050 |
Why?
|
| Scapula | 1 | 2018 | 9 | 0.040 |
Why?
|
| Ketoconazole | 1 | 2017 | 8 | 0.040 |
Why?
|
| Fluconazole | 1 | 2017 | 14 | 0.040 |
Why?
|
| Torso | 1 | 2017 | 16 | 0.040 |
Why?
|
| Forehead | 1 | 2017 | 19 | 0.040 |
Why?
|
| Pruritus | 1 | 2017 | 29 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2000 | 326 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 454 | 0.030 |
Why?
|